FDA/CDC

FDA wants data on role of flavored tobacco products in youth initiation


 

The Food and Drug Administration is seeking data on the role that flavors, including menthol, in tobacco products play in the initiation, use, and cessation of tobacco products, with an emphasis on how flavoring impacts young people.

“In the spirit of our commitment to preventing kids from using tobacco, we are taking a closer look at flavors in tobacco products to better understand their level of impact on youth initiation,” FDA Commissioner Scott Gottlieb, MD, said in statement. It is important “that we also explore how flavors, under a properly regulated framework that protects youth, may also be helping some currently addicted adult cigarette smokers switch to certain noncombustible forms of tobacco products.”

ecigarette teenager Thinkstockphotos.com
The agency issued an advance notice of proposed rule making March 20 that seeks information on flavoring in tobacco products to inform future policy making.

“Youth consistently report product flavoring as a leading reason for using tobacco products,” Dr. Gottlieb noted. “In fact, there is evidence indicating that youth tobacco users who reported their first tobacco was flavored had a higher prevalence of current tobacco product use, compared to youth whose product was not flavored.”

Pages

Recommended Reading

Flu vaccine did not protect children with acute leukemia
MDedge Hematology and Oncology
California tops state tobacco prevention spending
MDedge Hematology and Oncology
VIDEO: Cystic fibrosis patients need earlier, more frequent colorectal cancer screening
MDedge Hematology and Oncology
Young e-cigarette users graduating to the real thing
MDedge Hematology and Oncology
Analysis of Twitter lung cancer content reveals opportunity for clinicians
MDedge Hematology and Oncology
States judged on smoking cessation services
MDedge Hematology and Oncology
Preoperative exercise lowers postoperative lung resection complications
MDedge Hematology and Oncology
The T-cell repertoire in NSCLC: Therapeutic implications
MDedge Hematology and Oncology
Imfinzi approved for stage III unresectable NSCLC
MDedge Hematology and Oncology
MDedge Daily News: Could gut bacteria trigger autoimmune diseases?
MDedge Hematology and Oncology